ErlySign achieves CDSCO approval for clinical trials of oral cancer detection technology
India, April 8 -- ErlySign, a biotech startup located in Nagpur, has announced a significant milestone in the fight against cancer with approval from the Central Drugs Standard Control Organisation (CDSCO) for its active salivary biomarker study designed for early cancer detection.
Following a comprehensive year-long investigation and based on in-house validation data of 150 test samples, CDSCO has granted permission to ErlySign to proceed with large-scale clinical trials. Notably, during the initial studies, the active salivary biomarker study showcased remarkable performance, demonstrating a sensitivity of 98% and an unparalleled specificity of 100%.
The proprietary technology promises to revolutionise cancer detection through its adv...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.